Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma)

Y. Shoenfeld, E. Grunebaum, M. Laufer, N. Zurgil, R. Bakimer, A. Lunderschmidt, G. Valentini, G. Tirri, M. Blank

Research output: Contribution to journalArticlepeer-review


The relationship between anti-topoisomerase-I antibodies and clinical findings was studied in 191 patients with definite systemic sclerosis. This was done by performing ELISA to detect antibodies to recombinant topoisomerase-I. Antibodies to topoisomerase-I were found in 72 patients (37%) with systemic sclerosis, which is a higher percentage than reported in most previous reports on a large unselected population. In 43 patients the presence of antibodies to recombinant topoisomerase-I was confirmed using both the immunodiffusion method and ELISA, with similar results. When classified into diffuse versus limited disease, a significant difference in antibody prevalence was demonstrated (P < 0.005), thus indicating that anti-topoisomerase-I antibody detection with ELISA may assist in early identification of systemic sclerosis subtypes.

Original languageEnglish
Pages (from-to)537-542
Number of pages6
JournalIsrael Journal of Medical Sciences
Issue number7
StatePublished - Jul 1996
Externally publishedYes


  • Anti-Scl-70
  • Anti-topoisomerase-I
  • Autoantibodies
  • Autoimmunity
  • Systemic sclerosis


Dive into the research topics of 'Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma)'. Together they form a unique fingerprint.

Cite this